Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 11:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1705–1728 of 21,996 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Attention Deficit Hyperactivity Disorder, Attention Difficulties, Attention Deficit, Cognitive Deficit, Wellness
Interventions: Transcranial photobiomodulation, Sham transcranial photobiomodulation; Device
Lead sponsor: Francisco Gonzalez-Lima, PhD; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma, CRC (Colorectal Cancer), Metastatic Non-Small Lung Cell Cancer, Metastatic Colorectal Cancer (CRC), KRAS G12A, KRAS G12C, KRAS G12D, KRAS G12S, KRAS G12V, Metastatic Pancreatic Ductal Adenocarcinoma, Advanced Lung Carcinoma, Solid Tumor, Adult
Interventions: BBO-11818, Pembrolizumab, Platinum chemotherapy (cisplatin or carboplatin), Pemetrexed, Cetuximab, mFOLFOX6, BBO-10203, mFOLFIRINOX, Gemcitabine, Nab-paclitaxel; Drug
Lead sponsor: TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics); Industry
Eligibility: 18 Years and older
Enrollment: 665 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 12 more

Conditions: Lung Transplant, End Stage Lung Disease, Rejection
Interventions: Not listed
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2032
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Myelofibrosis (MF)
Interventions: Not applicable- observational study; Other
Lead sponsor: Swedish Orphan Biovitrum; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 5
States / cities: New Haven, Connecticut • Tampa, Florida • Columbus, Ohio + 2 more

Conditions: Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Mixed Phenotype Acute Leukemia
Interventions: Orca-T; Biological
Lead sponsor: Orca Biosystems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 6
States / cities: Los Angeles, California • Tampa, Florida • Hackensack, New Jersey + 3 more

Conditions: Epidermolysis Bullosa, Epidermolysis Bullosa Acquisita, Dystrophic Epidermolysis Bullosa, Recessive Dystrophic Epidermolysis Bullosa
Interventions: Immunoglobulin G; Biological
Lead sponsor: M. Peter Marinkovich; Other
Eligibility: 6 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Redwood City, California

Conditions: Opioid Use Disorder
Interventions: EMBED CDS, Nurse prompt to complete COWS, Provider Prompt, Patient facing materials, Optimized EMBED, Name of Intervention; Other
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 1,912 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 3
States / cities: Guilford, Connecticut • New Haven, Connecticut

Conditions: Clinical Deterioration
Interventions: PICTURE-Pediatric scores and alerts, Control Arm - Scores and alerts hidden; Device · Other
Lead sponsor: University of Michigan; Other
Eligibility: 30 Days to 25 Years
Enrollment: 375 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Malignant Digestive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Genitourinary System Neoplasm
Interventions: Non-Interventional Study; Other
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 103
States / cities: Kingman, Arizona • Fort Smith, Arkansas • Oakland, California + 81 more

Conditions: Head and Neck Carcinoma, Localized Head and Neck Carcinoma, Metastatic Head and Neck Carcinoma, Recurrent Head and Neck Carcinoma
Interventions: Personalized ultrafractionated stereotactic adaptive radiotherapy, Volume Modulated Arc Therapy, Computed Tomography, Positron Emission Tomography, Magnetic Resonance Imaging, Best Practice, University of Washington Quality of Life Scale, Version 4, Functional Assessment of Cancer Therapy-Head & Neck; Procedure · Radiation · Other + 1 more
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Human Immunodeficiency Virus
Interventions: Lenacapavir; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 75 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Candida Infection, Oral Thrush, Early Childhood Caries
Interventions: Not listed
Lead sponsor: Temple University; Other
Eligibility: 9 Months to 15 Months
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2028
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diffuse Intrinsic Pontine Glioma, High Grade Glioma, Embryonal Tumor, Ependymal Tumor
Interventions: C7R-GD2.CART cells (IV and ICV infusion); Genetic
Lead sponsor: Baylor College of Medicine; Other
Eligibility: 12 Months to 25 Years
Enrollment: 56 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2041
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Electronic Health Record Review, Epcoritamab, Magnetic Resonance Imaging, Obinutuzumab, Venetoclax; Procedure · Other · Biological + 1 more
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 7
States / cities: Duarte, California • Irvine, California • Long Beach, California + 4 more

Conditions: Cannabis Use, Cancer
Interventions: Not listed
Lead sponsor: HealthPartners Institute; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Saint Louis Park, Minnesota

Conditions: Endometriosis, Microbiome Dysbiosis, Gastrointestinal Symptoms
Interventions: Fiber, Placebo; Dietary Supplement
Lead sponsor: LOAM Science; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 140 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Adolescent Behavior
Interventions: Adolescent Mental Health Parenting Program for Child-Adult Relationship Enhancement (AMP-CARE); Behavioral
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Cary, North Carolina • Chapel Hill, North Carolina

Conditions: H3 K27M, Glioma
Interventions: Dordaviprone (ONC201), Dordaviprone (ONC201) + Placebo, Placebo; Drug · Other
Lead sponsor: Jazz Pharmaceuticals; Industry
Eligibility: Not listed
Enrollment: 510 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 67
States / cities: Phoenix, Arizona • La Jolla, California • Los Angeles, California + 48 more

Conditions: Parkinson Disease
Interventions: Red Light (PDT), Placebo; Device
Lead sponsor: University of Delaware; Other
Eligibility: 50 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Atopic Dermatitis
Interventions: ShA9 Topical Gel, Hydrocortisone Ointment, Clobetasol Ointment, Fluocinonide Ointment, Placebo (Vehicle) Topical Gel, Triamcinolone Ointment; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 6 Years and older
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 8
States / cities: San Diego, California • Denver, Colorado • Chicago, Illinois + 4 more

Conditions: Atrial Fibrillation, COVID-19, Cancer, Thrombosis
Interventions: [64Cu]FBP8, PET/MR, Blood Collection, Electrocardiogram; Drug · Device · Procedure
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 165 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Acute Spinal Cord Injury
Interventions: GlyBURIDE Oral Tablet; Drug
Lead sponsor: Francis Farhadi; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Lexington, Kentucky

Conditions: Heart Diseases, ASD - Atrial Septal Defect, VSD - Muscular Ventricular Septal Defect, PFO - Patent Foramen Ovale, PIVSD - Post Infarct Muscular Ventricular Septal Defect, Valvular Heart Disease
Interventions: Amplatzer™ Occlusion Devices, Epic™ Surgical Tissue Heart Valve devices; Device
Lead sponsor: Abbott Medical Devices; Industry
Eligibility: Not listed
Enrollment: 2,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2039
U.S. locations: 13
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 9 more

Conditions: Blunt Trauma to Abdomen, Wounds and Injuries, Abdomen Injury, Abdominal Injury, Abdomen, Acute
Interventions: Focused Assessment with Sonography for Trauma (FAST) Examination, No Intervention: Standard of Care - Without the FAST Examination; Diagnostic Test · Other
Lead sponsor: University of California, Davis; Other
Eligibility: Up to 17 Years
Enrollment: 4,650 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 6
States / cities: Sacramento, California • Aurora, Colorado • Atlanta, Georgia + 3 more

Search by objective public record fields.

Neurocognitive Effects of Non-Invasive Near-Infrared Light Stimulation

BBO-11818 in Adult Subjects With KRAS Mutant Cancer

GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation

Pacritinib Effectiveness in Real-world Settings

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Targeting Collagen VII Antibodies With IV IgG in Dystrophic Epidermolysis Bullosa

Adaptive Decision Support for Addiction Treatment Master

Predicting ICU Transfers and Other Unforeseen Events (PICTURE)-Pediatric

Surgical Thromboprophylaxis Practices in Oncology Patients Within the NCORP Network, STOP-VTE Study

Personalized Ultrafractionated Stereotactic Adaptive Radiotherapy for Palliative Head and Neck Cancer Treatment (PULS-Pal)

Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People With HIV Receiving Antiretroviral Therapy

Oropharyngeal Candidiasis (OPC) and S-ECC

C7R-GD2.CAR T Cells for Patients With GD2-expressing Brain Tumors (GAIL-B)

Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma, LonGEVity Trial

Cannabis Use Registry to Improve Overall Understanding of Symptoms (CURIOUS)

Trial Evaluating Nutritional Fiber in Digestive Symptoms of Endometriosis

Adolescent Mental Health Parenting Program for Child-Adult Relationship Enhancement

ONC201 in H3 K27M-mutant Diffuse Glioma Following Radiotherapy (the ACTION Study)

Light Therapy Intervention in Individuals With Parkinson's Disease

Targeted Investigation of Microbiome 2 Treat Atopic Dermatitis (TIME-2)

Positron Emission Tomography (PET) Imaging of Thrombosis

Spinal Cord Injury Neuroprotection With Glyburide

Abbott Structural Heart Device Registry

A Research Study of Abdominal Ultrasound (FAST) in Children With Blunt Torso Trauma